Company intelligence / Profile preview

Shanghai Zhongyao Biotechnology

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Zhongyao Biotech is a Shanghai-based biotechnology company specializing in the development of mRNA-based therapeutics and vaccines. The company leverages a proprietary mRNA-LNP (lipid nanoparticle) delivery platform to create next-generation treatments for infectious diseases and oncology. Their research focus includes optimizing mRNA stability and delivery efficiency to improve therapeutic outcomes. Zhongyao Biotech is currently advancing several candidates through the pre-clinical stage, aiming to address unmet medical needs in the global healthcare market.

Therapeutic areas: OncologyInfectious Diseases
Modalities: mRNA-based drugsLipid nanoparticle delivery therapyVaccine
Industry: Biotech

Drug pipeline

1 asset

Qizhi capsule

Unknown

Beyond the preview

Go deeper on Shanghai Zhongyao Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Zhongyao Biotechnology.

Explore the full profile